Journal Watch
July 2024
Gómez E, Montero JL, Molina E, et al. Longitudinal outcomes of Obeticholic acid therapy in ursodiol‐nonresponsive primary biliary cholangitis: Stratifying the impact of add‐on fibrates in real‐world practice. Alimentary Pharmacology & Therapeutics. 2024;59(12):1604-1615. doi:10.1111/apt.18004
Leite G, Barlow GM, Rashid M, et al. Characterization of the small bowel microbiome reveals different profiles in human subjects who are overweight or have obesity. American Journal of Gastroenterology. 2024;119(6):1141-1153. doi:10.14309/ajg.0000000000002790
Peyrin-Biroulet L, Chapman JC, Colombel J-F, et al. Risankizumab versus ustekinumab for moderate-to-severe crohn’s disease. New England Journal of Medicine. 2024;391(3):213-223. doi:10.1056/nejmoa2314585
Singh A, Goyal MK, Midha V, et al. Tofacitinib in acute severe ulcerative colitis (tacos): A randomized controlled trial. American Journal of Gastroenterology. 2023;119(7):1365-1372. doi:10.14309/ajg.0000000000002635
August 2024
Gala K, Yao R, Ghusn W, Vargas E. Effect of glucagon-like peptide-1 receptor agonists on bowel preparation for colonoscopy. Gastrointestinal Endoscopy. 2023;97(6). doi:10.1016/j.gie.2023.04.551
Kumar M, Venishetty S, Jindal A, et al. Tranexamic acid in upper gastrointestinal bleed in patients with cirrhosis: A randomized controlled trial. Hepatology. 2024;80(2):376-388. doi:10.1097/hep.0000000000000817
Wang H, Ahn JY, Noh JH, et al. Clinical outcomes of argon plasma coagulation for the treatment of gastric low-grade dysplasia. Gastrointestinal Endoscopy. 2024;100(2). doi:10.1016/j.gie.2024.01.025
Wiklund A-K, Santoni G, Yan J, et al. Risk of esophageal adenocarcinoma after Helicobacter pylori eradication treatment in a population-based multinational cohort study. Gastroenterology. 2024;167(3). doi:10.1053/j.gastro.2024.03.016
September 2024
Lo G-H, Yeh J-H, Tseng C-H, et al. A noninferiority trial comparing 2 days vs 5 days of Terlipressin and ceftriaxone in terms of 5-day rebleeding for patients with acute gastroesophageal variceal hemorrhage. American Journal of Gastroenterology. 2024;119(9):1821-1830. doi:10.14309/ajg.0000000000002776
Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2A trial. Nature Medicine. 2024;30(7):2037-2048. doi:10.1038/s41591-024-03018-2
Soriani P, Biancheri P, Bonura GF, et al. Over-the-scope clip as first-line treatment of peptic ulcer bleeding: A multicenter randomized controlled trial (top study). Endoscopy. 2024;56(09):665-673. doi:10.1055/a-2303-4824
Vantanasiri K, Joseph A, Sachdeva K, et al. Rates of recurrent intestinal metaplasia and dysplasia after successful endoscopic therapy of Barrett’s Neoplasia by endoscopic mucosal resection vs endoscopic submucosal dissection and ablation: A large North American Multicenter cohort. American Journal of Gastroenterology. 2024;119(9):1831-1840. doi:10.14309/ajg.0000000000002798
October 2024
Gao W, Liu J, Wang X, et al. Simplified helicobacter pylori therapy for patients with penicillin allergy: A randomised controlled trial of vonoprazan-tetracycline dual therapy. Gut. 2024;73(9):1414-1420. doi:10.1136/gutjnl-2024-332640
Redd WD, Holub JL, Nichols HB, Sandler RS, Peery AF. Follow-up colonoscopy for detection of missed colorectal cancer after diverticulitis. Clinical Gastroenterology and Hepatology. 2024;22(10):2125-2133. doi:10.1016/j.cgh.2024.03.036
Rokkas T, Ekmektzoglou K, Niv Y, Graham DY. Comparative efficacy and safety of potassium-competitive acid blocker-based dual, triple, and quadruple regimens for first-line helicobacter pylori infection treatment: A systematic review and network meta-analysis. American Journal of Gastroenterology. 2024;120(4):787-798. doi:10.14309/ajg.0000000000003084
Wiklund A-K, Santoni G, Yan J, et al. Risk of esophageal adenocarcinoma after Helicobacter pylori eradication treatment in a population-based multinational cohort study. Gastroenterology. 2024;167(3). doi:10.1053/j.gastro.2024.03.016
November 2024
Sands BE, Feagan BG, Peyrin-Biroulet L, et al. Phase 2 trial of anti-TL1A monoclonal antibody Tulisokibart for ulcerative colitis. New England Journal of Medicine. 2024;391(12):1119-1129. doi:10.1056/nejmoa2314076
Tseng C-H, Chang L-C, Wu J-L, et al. Bleeding risk of cold versus hot snare polypectomy for pedunculated colorectal polyps measuring 10 mm or less: Subgroup analysis of a large randomized controlled trial. American Journal of Gastroenterology. 2024;119(11):2233-2240. doi:10.14309/ajg.0000000000002847
Virmani S, Kedia S, Bajaj A, et al. Potassium-rich diet (coconut water) modulates gut microbiome and induces clinical remission in patients with mild to moderate ulcerative colitis: Double blind randomized placebo-controlled trial. Clinical Gastroenterology. Published online June 2023. doi:10.1136/gutjnl-2023-iddf.198
Yang Y, Li Y, Huang C, Yu T, Li J. Evaluation of the cold vs hot snare endoscopic resection of large nonpedunculated colorectal polyps in the german chronicle trial. Gastroenterology. 2025;168(2):428-429. doi:10.1053/j.gastro.2024.09.044
January 2025
Chandan S, Khan SR, Deliwala SS, et al. Risk of de novo barrett’s esophagus post sleeve gastrectomy: A systematic review and meta-analysis of studies with long-term follow-up. Clinical Gastroenterology and Hepatology. 2025;23(1). doi:10.1016/j.cgh.2024.06.041
Cho E, Kim S-H, Park CH, et al. Tailored hydration with lactated Ringer’s solution for postendoscopic retrograde cholangiopancreatography pancreatitis prevention: A randomized controlled trial. American Journal of Gastroenterology. 2024;119(12):2426-2435. doi:10.14309/ajg.0000000000002903
Meyer A, Miranda S, Drouin J, Weill A, Carbonnel F, Dray-Spira R. Safety of vedolizumab and ustekinumab compared with Anti-TNF in pregnant women with inflammatory bowel disease. Clinical Gastroenterology and Hepatology. 2025;23(1). doi:10.1016/j.cgh.2023.12.029
February 2025
Chavannes M, Dolinger MT, Cohen-Mekelburg S, Abraham B. AGA clinical practice update on the role of intestinal ultrasound in inflammatory bowel disease: Commentary. Clinical Gastroenterology and Hepatology. 2024;22(9). doi:10.1016/j.cgh.2024.04.039
Dongelmans EJ, Hirode G, Hansen BE, et al. Predictors of hepatic flares after nucleos(t)ide analogue cessation – results of a global cohort study (retract-B study). Journal of Hepatology. 2025;82(3):446-455. doi:10.1016/j.jhep.2024.08.015
Oh J-H, Kim H-S, Cheung DY, et al. Randomized, double-blind, active-controlled phase 3 study to evaluate efficacy and safety of Zastaprazan compared with Esomeprazole in erosive esophagitis. American Journal of Gastroenterology. 2024;120(2):353-361. doi:10.14309/ajg.0000000000002929
Sanyal AJ, Bedossa P, Fraessdorf M, et al. A phase 2 randomized trial of Survodutide in MASH and fibrosis. New England Journal of Medicine. 2024;391(4):311-319. doi:10.1056/nejmoa2401755
March 2025
Drews J, Zachäus M, Kleemann T, et al. Multicentre randomised controlled trial of a self-assembling haemostatic gel to prevent delayed bleeding following endoscopic mucosal resection (purple trial). Gut. Published online February 23, 2025. doi:10.1136/gutjnl-2024-334229
Jeppesen PB, Vanuytsel T, Subramanian S, et al. Glepaglutide, a long-acting glucagon-like peptide-2 analogue, reduces parenteral support in patients with short bowel syndrome: A phase 3 randomized controlled trial. Gastroenterology. 2025;168(4). doi:10.1053/j.gastro.2024.11.023
Narula N, Pray C, Hamam H, et al. Tofacitinib for hospitalized acute severe ulcerative colitis management (The Triumph Study). Crohn’s & Colitis 360. 2024;7(1). doi:10.1093/crocol/otaf013
Tan MC, Li Z, Patel KK, et al. A high-resolution Microendoscope improves esophageal cancer screening and surveillance: Implications for underserved global settings based on an international randomized controlled trial. Gastroenterology. 2025;168(3). doi:10.1053/j.gastro.2024.10.025